The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals JAZZ Epidiolex, a CBD-based medicine, to patients suffering from tuberous sclerosis complex (TSC). This means that patients who use this cannabidiol product in the U.K. will be reimbursed starting on March 1.
“We’re thrilled that people with TSC in England will now have access to cannabidiol, a potentially life-changing medicine for the eight in 10 people in the UK who have TSC and also difficult-to-treat TSC-related epilepsy,” said Dr. Pooja Takhar of the Tuberous Sclerosis Association.
Tuberous sclerosis complex is known as a dominant cause of genetic epilepsy. It induces the growth of benign tumors in the brain, heart, lungs, kidneys, skin and eyes, with epilepsy being the most frequent neurological component. According to TSC Alliance, at least two children are born each day with TSC. Around one million people across the globe suffer from this disease, with around 50,000 in the U.S., and between 3,700 to 11,000 in the U.K.
What Is Epidiolex?
Epidiolex is the first FDA-authorized CBD medicine for treating children with severe forms of epilepsy. The medicine was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome, and last July for treating seizures related to tuberous sclerosis complex. Epidiolex’s net product sales were $463 million in 2021, whereas in just the first three quarters of…
Original Author Link click here to read complete story..
